T. Rowe Price Investment Management’s Immunovant IMVT Stock Holding History

T. Rowe Price Investment Management’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$85.6M	Sell	2,222,101 -1,390,759	-38%	-$42.4M	0.06%	300
2026 Q1	$89.7M	Sell	3,612,860 -1,447,539	-29%	-$37.5M	0.06%	269
2025 Q4	$129M	Sell	5,060,399 -104,299	-2%	-$2.33M	0.08%	218
2025 Q3	$83.3M	Sell	5,164,698 -1,714,258	-25%	-$27.8M	0.05%	298
2025 Q2	$110M	Buy	6,878,956 +984,132	+17%	+$14.9M	0.07%	262
2025 Q1	$101M	Buy	5,894,824 +777,590	+15%	+$16.3M	0.07%	280
2024 Q4	$127M	Buy	5,117,234 +1,786,217	+54%	+$50.7M	0.08%	247
2024 Q3	$95M	Buy	3,331,017 +1,705,797	+105%	+$50.3M	0.06%	305
2024 Q2	$42.9M	Buy	+1,625,220	New	+$46.2M	0.03%	406

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management's IMVT Position: Q2 2026 in Review

T. Rowe Price Investment Management reduced its Immunovant (IMVT) stake by 38% in Q2 2026, selling an estimated $42.4M and leaving 2,222,101 shares worth $85.6M. The position accounts for 0.06% of the portfolio, ranked #300.

T. Rowe Price Investment Management first reported a position in IMVT in Q2 2024 and has held it in 9 quarters since. The position peaked at $129M in Q4 2025. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

T. Rowe Price Investment Management held 2,222,101 shares of Immunovant worth $85.6M as of Q2 2026.
T. Rowe Price Investment Management sold 1,390,759 Immunovant shares in Q2 2026, an estimated $42.4M.
Immunovant made up 0.06% of T. Rowe Price Investment Management's portfolio in Q2 2026, its #300 holding.
T. Rowe Price Investment Management first reported a position in Immunovant in Q2 2024 and has held it in 9 quarters since.
T. Rowe Price Investment Management's Immunovant position peaked at $129M in Q4 2025.
226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.